Indian Glaucoma and Cataract Surgery Devices Market by Product, Surgery Type, and End User - Opportunity Analysis and Industry Forecast, 2017-2023

  • ID: 4580564
  • Report
  • Region: India
  • 183 pages
  • Allied Analytics LLP
1 of 4
The Indian glaucoma and cataract surgery devices market was valued at $164 million in 2016, and is expected to reach $321 million by 2023, registering a CAGR of 10.1% from 2017 to 2023. Glaucoma is a disease that causes vision loss owing to optic nerve damage. Cataract is the formation of dense, cloudy area that could affect the vision. The devices and instruments such as phacoemulsification systems, intraocular lenses, implants and stents, and glaucoma drainage aid in glaucoma and cataract surgical procedure to treat both the conditions efficiently.

Increase in prevalence of cataract disease as well as technological advancements in ophthalmic devices drives the market growth. Furthermore, increase in incidence of glaucoma and growth in geriatric population are projected to supplement the market growth. However, low awareness among people related to eye disorders and budget constrains caused by the high cost of these surgical devices hamper the market growth. Moreover, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma offer profitable opportunities for market expansion.

The Indian glaucoma and cataract surgery devices market is segmented into product, surgery type, and end user. Based on product, the market is bifurcated into glaucoma and cataract surgery devices. The glaucoma surgery devices market is further divided into glaucoma drainage device, glaucoma laser device, and implant & stent. The cataract surgery device is further classified into intraocular lens (IOL), ophthalmic viscoelastic device (OVD), and phacoemulsification equipment. Based on the surgery type, glaucoma surgery is bifurcated into conventional glaucoma surgery and minimally invasive glaucoma surgery; whereas, cataract surgery is further classified into phacoemulsification, extracapsular cataract extraction (ECCE) surgery, femtosecond laser surgery, and others. The end users are classified into hospital, ophthalmology clinic, and outpatient surgical center. Based on zones, the market is classified into north zone, east zone, west zone, south zone, central zone, and north-east zone.

KEY MARKET BENEFITS FOR STAKEHOLDERS

This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on zone assists in understanding the regional market to assist in strategic business planning.
The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Product

Glaucoma Surgery Device
Implant & Stent
Glaucoma Drainage
Glaucoma Laser Device
Cataract Surgery Device
Intraocular Lens
Ophthalmic Viscoelastic Device
Phacoemulsification System

By Surgery Type

Glaucoma Surgery
Conventional Glaucoma Surgery
Minimally Invasive Glaucoma Surgery
Cataract Surgery
Phacoemulsification
Extracapsular Cataract Extraction (ECCE) Surgery
Femtosecond Laser Surgery
Others

By End Users

Hospital
Ophthalmology Clinic
Outpatient Surgery Center

By Zone

North Zone
East Zone
West Zone
South Zone
Central Zone
North-East Zone

KEY PLAYERS PROFILED

Alcon, Inc. (Novartis AG)
New World Medical, Inc.
Johnson & Johnson
Bausch & Lomb, Inc. (Valeant Pharmaceuticals International, Inc.)
Topcon Corporation
Lumenis Ltd.
Allergan plc.
Carl Zeiss Meditec AG
Essilor International S.A.
HAAG-Streit Holding AG
Nidek Co., Ltd.
Ziemer Ophthalmic Systems AG
Ellex Medical Lasers Ltd.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Local vs Import Glaucoma and Cataract Devices Analysis
3.4. Porters Five Forces Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Technological advancements in cataract and glaucoma surgery devices
3.5.1.2. Rise in geriatric population
3.5.1.3. Increase in focus on training for eye physicians and improve customer awareness
3.5.2. Restrains
3.5.2.1. Low awareness among people related to eye disorders
3.5.2.2. High cost of cataract and glaucoma surgeries and risk of post-operative complications associated with the glaucoma surgeries
3.5.3. Opportunity
3.5.3.1. Increase in transition toward minimally invasive surgeries for glaucoma treatment

CHAPTER 4: INDIAN GLAUCOMA AND CATARACT SURGERY DEVICES MARKET BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast, by product
4.2. Glaucoma Surgery Devices
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast, by type
4.2.4. Market size and forecast, by zone
4.2.5. Implant & stent
4.2.5.1. Market size and forecast, by zone
4.2.6. Glaucoma drainage
4.2.6.1. Market size and forecast, by zone
4.2.7. Glaucoma laser device
4.2.7.1. Market size and forecast, by zone
4.3. Cataract Surgery Devices
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast, by type
4.3.4. Market size and forecast, by zone
4.3.5. Intraocular lens
4.3.5.1. Market size and forecast, by zone
4.3.6. Ophthalmic viscoelastic device
4.3.6.1. Market size and forecast, by zone
4.3.7. Phacoemulsification system
4.3.7.1. Market size and forecast, by zone

CHAPTER 5: INDIAN GLAUCOMA AND CATARACT SURGERY DEVICES MARKET BY SURGERY TYPE
5.1. Overview
5.2. Glaucoma Surgery Type
5.2.1. Market size and forecast, by surgery type
5.2.2. Conventional glaucoma surgery
5.2.2.1. Market size and forecast, by zone
5.2.3. Minimally invasive glaucoma surgery
5.2.3.1. Market size and forecast, by zone
5.3. Cataract Surgery Type
5.3.1. Market size and forecast, by surgery type
5.3.2. Phacoemulsification
5.3.2.1. Market size and forecast, by zone
5.3.3. Extracapsular cataract extraction (ECCE) surgery
5.3.3.1. Market size and forecast, by zone
5.3.4. Femtosecond laser surgery
5.3.4.1. Market size and forecast, by zone
5.3.5. Others
5.3.5.1. Market size and forecast, by zone

CHAPTER 6: INDIAN GLAUCOMA AND CATARACT SURGERY DEVICES MARKET BY END USERS
6.1. Overview
6.1.1. Market size and forecast, by end user
6.2. Hospital
6.2.1. Market size and forecast, by zone
6.3. Ophthalmology Clinic
6.3.1. Market size and forecast, by zone
6.4. Outpatient Surgery Centers
6.4.1. Market size and forecast, by zone

CHAPTER 7: INDIAN GLAUCOMA AND CATARACT SURGERY DEVICES MARKET BY ZONE
7.1. Overview
7.1.1. Market size and forecast, by zone
7.2. North Zone
7.2.1. Market size and forecast, by product
7.2.2. Market size and forecast, by surgery type
7.2.3. Market size and forecast, by end users
7.3. East Zone
7.3.1. Market size and forecast, by product
7.3.2. Market size and forecast, by surgery type
7.3.3. Market size and forecast, by end users
7.4. West Zone
7.4.1. Market size and forecast, by product
7.4.2. Market size and forecast, by surgery type
7.4.3. Market size and forecast, by end users
7.5. South Zone
7.5.1. Market size and forecast, by product
7.5.2. Market size and forecast, by surgery type
7.5.3. Market size and forecast, by end users
7.6. Central Zone
7.6.1. Market size and forecast, by product
7.6.2. Market size and forecast, by surgery type
7.6.3. Market size and forecast, by end users
7.7. North-East Zone
7.7.1. Market size and forecast, by product
7.7.2. Market size and forecast, by surgery type
7.7.3. Market size and forecast, by end users

CHAPTER 8: COMPANY PROFILES
8.1. Allergan Plc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Carl Zeiss Meditec AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Ellex Medical Lasers Ltd.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Essilor International S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. HOYA Corporation
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Johnson & Johnson
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Lumenis Ltd.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. Metall Zug AG (HAAG-Streit Holding AG)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. New World Medical, Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Product portfolio
8.10. Nidek Co., Ltd.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
8.11. Novartis International AG (Alcon Inc.)
8.11.1. Company overview
8.11.2. Company snapshot
8.11.3. Operating business segments
8.11.4. Product portfolio
8.11.5. Business performance
8.11.6. Key strategic moves and developments
8.12. Topcon Corporation.
8.12.1. Company overview
8.12.2. Company snapshot
8.12.3. Operating business segments
8.12.4. Product portfolio
8.12.5. Business performance
8.12.6. Key strategic moves and developments
8.13. Valeant pharmaceuticals International, Inc. (Bausch & Lomb Incorporated)
8.13.1. Company overview
8.13.2. Company snapshot
8.13.3. Operating business segments
8.13.4. Product portfolio
8.13.5. Business performance
8.13.6. Key strategic moves and developments
8.14. Ziemer Ophthalmic Systems AG
8.14.1. Company overview
8.14.2. Company snapshot
8.14.3. Product portfolio
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Indian Glaucoma and Cataract Surgery Devices Market by Product, Surgery Type, End User, and Zone Opportunity Analysis and Industry Forecast, 20172023," the Indian glaucoma and cataract surgery devices market accounted for $164 million in 2016, and is expected to reach $321 million by 2023, registering a CAGR of 10.1% from 2017 to 2023. West zone is the highest contributor in the Indian glaucoma and cataract surgery devices market in 2016; however, north zone is expected to witness the highest growth rate during the forecast period.

Glaucoma is caused by the damage to the optic nerve, and if not treated accurately can eventually lead to loss of vision. It is commonly prevalent in the geriatric population. The most commonly occurring type of glaucoma is the open-angle glaucoma. Apart from the conventional approaches such as laser surgeries, development of novel drainage devices and stents propel the market growth. Cataract is an eye-related disease in which clouding of the eye lens is observed that leads to impaired vision. Cataract surgery is the removal of clouded natural lens, and involves implantation of intraocular lens.

Increase in incidence of glaucoma and growth in geriatric population drives the market growth. Furthermore, increase in prevalence of cataract disease as well as technological advancements in ophthalmic devices are projected to supplement the market growth. However, dearth of skilled professionals and risk of post-operative complications associated with glaucoma surgeries hamper this growth. Moreover, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma offer profitable opportunities for market expansion.

Among the types of surgery for glaucoma, conventional glaucoma surgery is dominant segment owing to the fewer complications caused by the use of these devices, making them the first choice of the surgeons for the treatment of certain types of glaucoma.

By end user, the hospital segment generated the highest revenue in 2016, and is set to continue its dominance throughout the forecast period. However, outpatient surgical center segment is expected to witness a high growth rate on account of the increase in the number of glaucoma laser surgeries being carried out in outpatient surgical facilities and large-scale utilization of glaucoma drainage devices such as tube shunts in these facilities.

Key Findings of the Indian Glaucoma And Cataract Surgery Devices Market

Minimally invasive glaucoma surgery is projected to grow at the highest rate during the analysis period.
West zone dominated Indian glaucoma and cataract surgery devices market in 2016, and is projected to continue its dominance in future.
Phacoemulsification systems is expected to grow at the fastest pace during the forecast period.
Glaucoma drainage devices is the largest contributor among the product segments in 2016.
Intraocular lens generated the highest revenue, and is expected to continue its dominance in future.

The key players operating in the Indian glaucoma and cataract surgery devices market include Alcon, Inc. (Novartis AG), New World Medical, Inc., Johnson & Johnson, Bausch & Lomb, Inc. (Valeant Pharmaceuticals International, Inc.), Topcon Corporation, Lumenis Ltd., Allergan plc., Carl Zeiss Meditec AG, Essilor International S.A., HAAG-Streit Holding AG, Nidek Co., Ltd., Ziemer Ophthalmic Systems AG, and Ellex Medical Lasers Ltd. Other prominent players in the value chain include Santen Pharmaceutical Co., Ltd., Abbott Laboratories, Inc., Zabbys, STAAR Surgical Company, Hoya Corporation, and Aurolab.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll